GSK-2130579-A

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGSK-2130579-A
Drug Alias NameWT1-A10+AS01B ASCIAcute myeloid leukaemia vaccine2130579-AGSK-2130579-A
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulantsWilms' Tumour 1 (WT1)-directed cytolytic effects
TargetsWilms' Tumour 1
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A